Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L A Price

Showing results (71-80 of 106) with videos related to

Pageof 11
Sort By:
Eye (London, England)|January 16, 2016
Low-energy light bulbs, computers, tablets and the blue light hazardJ B O'Hagan, M Khazova, L L A Price
Lancet (London, England)|January 4, 1986
Head and neck cancerB T Hill, L A Price, K D MacRae
Clinical Oncology|September 1, 1977
DDMP and selective folinic acid protection in the treatment of malignant disease: a further reportL A Price, B T Hill, J H Goldie
British Medical Journal|April 5, 1975
Methodichlorophen as anti-tumor drugL A Price, J H Goldie, B T Hill
European Journal of Cancer|August 1, 1972
Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion patternJ H Goldie, L A Price, K R Harrap
Radiation Protection Dosimetry|September 13, 2015
DYNAMIC RESPONSE OF CCD ARRAY SPECTRORADIOMETERSKatarzyna Anna Baczynska, Luke L A Price, Marina Khazova
Cancer Investigation|January 1, 1987
The promising role of safe initial non-cisplatin-containing combination chemotherapy in nasopharyngeal tumorsB T Hill, L A Price, K D MacRae
Molecular Pharmacology|October 1, 1996
Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathwayL A Price, J Strnad, M H Pausch, et al.
Archiv Fur Geschwulstforschung|January 1, 1981
Cell population kinetics - experimental methods and their in vivo relevance for human cancer chemotherapyB T Hill, R D Whelan, H T Rupniak, et al.
American Journal of Clinical Oncology|August 1, 1984
24-hour combination chemotherapy without cisplatin in patients with recurrent or metastatic head and neck cancerB T Hill, H J Shaw, V M Dalley, et al.
Pageof 11

Showing results (71-80 of 106) with videos related to

Sort By:
Pageof 11
Eye (London, England)|January 16, 2016
Low-energy light bulbs, computers, tablets and the blue light hazardJ B O'Hagan, M Khazova, L L A Price
Lancet (London, England)|January 4, 1986
Head and neck cancerB T Hill, L A Price, K D MacRae
Clinical Oncology|September 1, 1977
DDMP and selective folinic acid protection in the treatment of malignant disease: a further reportL A Price, B T Hill, J H Goldie
British Medical Journal|April 5, 1975
Methodichlorophen as anti-tumor drugL A Price, J H Goldie, B T Hill
European Journal of Cancer|August 1, 1972
Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion patternJ H Goldie, L A Price, K R Harrap
Radiation Protection Dosimetry|September 13, 2015
DYNAMIC RESPONSE OF CCD ARRAY SPECTRORADIOMETERSKatarzyna Anna Baczynska, Luke L A Price, Marina Khazova
Cancer Investigation|January 1, 1987
The promising role of safe initial non-cisplatin-containing combination chemotherapy in nasopharyngeal tumorsB T Hill, L A Price, K D MacRae
Molecular Pharmacology|October 1, 1996
Pharmacological characterization of the rat A2a adenosine receptor functionally coupled to the yeast pheromone response pathwayL A Price, J Strnad, M H Pausch, et al.
Archiv Fur Geschwulstforschung|January 1, 1981
Cell population kinetics - experimental methods and their in vivo relevance for human cancer chemotherapyB T Hill, R D Whelan, H T Rupniak, et al.
American Journal of Clinical Oncology|August 1, 1984
24-hour combination chemotherapy without cisplatin in patients with recurrent or metastatic head and neck cancerB T Hill, H J Shaw, V M Dalley, et al.
Pageof 11